Table 2.
Univariate | Multivariate model 1* | Multivariate model 2** | |||||||
---|---|---|---|---|---|---|---|---|---|
HR | 95%CI | p | HR | 95%CI | p | HR | 95%CI | p | |
Age (continuous) | 1.01 | 0.90–1.03 | 0.446 | – | – | – | – | – | – |
Grade 1-2 | Ref | – | – | – | – | – | – | ||
Grade 3 | 1.29 | 0.55–3.02 | 0.553 | ||||||
Stage I | Ref | Ref | Ref | ||||||
Stage II-III | 2.07 | 1.10–3.89 | 0.024 | 3.05 | 1.83–5.08 | <0.001 | 2.34 | 1.26–4.47 | 0.008 |
TILs (1% increments) | 0.98 | 0.96–0.99 | 0.005 | – | – | – | 0.98 | 0.96–0.99 | 0.004 |
AR – | Ref | Ref | Ref | ||||||
AR + | 1.82 | 1.10–3.02 | 0.020 | 1.74 | 1.05–2.88 | 0.032 | 1.57 | 0.94–2.61 | 0.084 |
HR, hazard ratio; CI, confidence interval; p, p-value; TILs, tumor infiltrating lymphocytes, AR, androgen receptor.
Including stage and AR.
Including stage, AR and TILs.